Prediction of regression and relapse of endometrial hyperplasia with conservative therapy

Obstetrics and Gynecology

Volumn 121, Issue 6, 2013, Pages 1165-1171

  Gallos, Ioannis D ^a   Ganesan, Raji ^a   Gupta, Janesh K ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LEVONORGESTREL; MEDROXYPROGESTERONE; NORETHISTERONE; TAMOXIFEN;

ADULT; ARTICLE; BODY MASS; COHORT ANALYSIS; DRUG TREATMENT FAILURE; ENDOMETRIUM HYPERPLASIA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HYSTERECTOMY; INTRAUTERINE CONTRACEPTIVE DEVICE; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; RETROSPECTIVE STUDY; SURVIVAL;

EID: 84879119679     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0b013e31828cb563     Document Type: Article

References (16)

1. Reed SD, Newton KM, Clinton WL, Epplein M, Garcia R, Allison K, et al. Incidence of endometrial hyperplasia. Am J Obstet Gynecol 2009;200:678-6.
2. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer 1985;56:403-12.
3. Gallos ID, Ofinran O, Shehmar M, Coomarasamy A, Gupta JK. Current management of endometrial hyperplasia - a survey of United Kingdom consultant gynaecologists. Eur J Obstet Gynecol Reprod Biol 2011;158:305-7.
4. Trimble CL, Kauderer J, Zaino R, Silverberg S, Lim PC, Burke JJ, et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 2006;106:812-9.
5. Gallos ID, Shehmar M, Thangaratinam S, Papapostolou TK, Coomarasamy A, Gupta JK. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol 2010;203: 547-10.
6. Gallos ID, Devey J, Ganesan R, Gupta JK. Predictive ability of estrogen (ER), progesterone (PR), COX-2, Mlh1, and Bcl-2 expression for regression and relapse of endometrial hyperplasia treated with LNG-IUS: a prospective cohort study. Gynecol Oncol 2013 Apr 17. pii: S0090-8258(13)00236-9. doi: 10. 1016/j.ygyno.2013.04.016. [Epub ahead of print].
7. Gallos ID, Krishan P, Shehmar M, Ganesan R, Gupta JK Relapse of endometrial hyperplasia after conservative treatment: a cohort study with long term follow up. Hum Reprod 2013 Mar 6 [Epub ahead of print].
8. Ferenczy A, Gelfand M. The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia. Am J Obstet Gynecol 1989;160:126-31.
9. Weber AM, Belinson JL, Piedmonte MR. Risk factors for endometrial hyperplasia and cancer among women with abnormal bleeding. Obstet Gynecol 1999;93:594-8.
10. Lin DY, Wei JL. The robust inference for the Cox proportional hazards model. J Am Stat Assoc 1989;84:1074-8.
11. Cox DR. Regression models and life tables. J R Stat Soc 1972; 34:187-220.
12. Klein JP, Moeschberger ML. Survival analysis: techniques for censored and truncated data. 2nd ed. New York (NY): Springer; 2003.
13. Rubin DB. A non-iterative algorithm for least squares estimation of missing values in any analysis of variance design. J R Stat Soc 1972;21:136-41.
14. Schafer JL. Analysis of incomplete multivariate data. Boca Raton (FL): Chapman & Hall/CRC; 1997.
15. Gallos ID, Yap J, Rajhkowa M, Coomarasamy A, Luesley DM, Gupta JK. Regression, relapse and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol. 2012;204:266.e1-12.
16. Anderson B, Connor JP, Andrews JI, Davis CS, Buller RE, Sorosky JI, et al. Obesity and prognosis in endometrial cancer. Am J Obstet Gynecol 1996;174:1171-9.